N
N
N
H
N
N
O
CN
N
N
N
H
N
N
CN
Tofacitinib
Ruxolitinib
N
N
N
H
N
Oclacitinib
S
NHMe
O
O
N
N
N
H
N
N
Baricitinib
N
NC
S
O O
(veterinary)
b) Approved JAK
inhibitors:
c) Advanced investigational
JAK inhibitors:
N
N
O
N
F
CF 3
N
NC
N
N
N
N
H
Itacitinib
N
N
N
H
N
NH
O
S
O
PF-04965842
O
N
N
H
N
N
HN
O
CN
Momelotinib
N
N
N
N
H
N
O
N
H
CF 3
Upadacitinib
Pacritinib
N
N
N
H
O
O
O
N
O
HN
CF 3
NH
N
N
N
H
N
Decernotinib
O
NH
N N
N
S
N
O
O
Filgotinib
6
7
8
9
10
11
12
13
14
15
16
N
O
HN
O
O
N
N
HN
Cl
F
Afatinib
N
N
N
H
N
HN
O
N
N
O
Osimertinib
N
O
HN
O
N
H N
N
Cl
O
N
Neratinib
NH 2
O
N
N
N
O
N
N
Ibrutinib
O
H
N
N
NH 2
N
N
N
O
N
Acalabrutinib
1
2
3
4
5
a) Approved covalent kinase
inhibitors:
Fig. 2 (a) Currently approved covalent kinase inhibitors. (b) Currently approved JAK inhibitors.
(c) Advanced investigational JAK inhibitors
Covalent Janus Kinase 3 Inhibitors
229